Brief: Urogen Pharma Reports Q1 Results
13/05/2021 12:54
May 13 (Reuters) - Urogen Pharma Ltd UR8.F :
* Q1 LOSS PER SHARE $1.17
* AS OF MARCH 31, 2021, CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES TOTALED $75.9 MILLION
Source text for Eikon: ID:nBw5WHyxLa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors